The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

SolidddVisionTM smartglasses, the first true vision correction for people living with vision loss due to macula ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Citi has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Rates of nearsightedness, or myopia, are skyrocketing in kids—and scientists say it has to do with how little time they’re ...

Fintel reports that on January 7, 2025, Citigroup initiated coverage of EyePoint Pharmaceuticals (NasdaqGM:EYPT) with a Buy ...

In September, ONL announced the closing of a $65 million Series D financing round, led by Johnson & Johnson Innovation – JJDC, Inc. The Series D funding supports the advancement of the development of ...

Range Financial Group LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the ...